To investigate the outcomes of patients with upper tract urothelial carcinoma (UTUC) with non-definitive therapy, which currently remains unknown.
Introduction
An estimated 5-10% of urothelial malignancies are present in the upper tract and collecting system [1] . In general, the primary form of therapy for non-metastatic upper tract urothelial carcinoma (UTUC) is surgery, which is dictated by tumour location and includes either radical nephroureterectomy, segmental ureterectomy, or for select cases, endoscopic resection [2] . As the median age of diagnosis for UTUC is~75 years [3] , many patients may not be candidates for surgical management due to poor functional status or other comorbidities [4] . In addition, patients with poor baseline renal insufficiency may be precluded from nephroureterectomy due to concerns of postoperative end-stage renal disease (ESRD) with potential progression to dialysis [5] . Moreover, radical nephroureterectomy for UTUC has been associated with a 26-38% risk of postoperative complications and can pose significant issues even in the patient who is deemed a surgical candidate [6] [7] [8] .
There is an absence of information regarding the optimal management for patients with localised UTUC who are poor candidates for 'gold standard' extirpative therapy or even repeat endoscopic management. For those without symptoms, initial conservative approaches are frequently employed, with consideration of systemic therapy upon symptomatic progression. This strategy of 'watchful waiting' has been adopted in other malignancies including prostate cancer for patients who refuse definitive therapy or have a high risk of significant complications and are offered androgendeprivation therapy upon symptomatic progression [9] . Watchful waiting in renal tumours has also been accepted in individuals who are not candidates for definitive local therapy. Understandably, UTUC presents a higher risk cohort of patients with cancer.
In patients diagnosed with UTUC who possess a limited lifeexpectancy, there has been limited information on the natural history of the disease with a watchful waiting approach. This management strategy could have the benefit of avoiding surgery whilst allowing treatment with chemotherapy should disease progress. Whilst, cisplatin-based chemotherapy has significant toxicity for elderly patients with comorbidities, the newly approved immunotherapy options including pembrolizumab, durvalumab, atezolizumab, and nivolumab have a much better toxicity profile with durable remission observed for a wide variety of cancers and could be considered in a subset of patients if efficacy for UTUC is confirmed [10] .
An improved understanding of the survival outcomes and impact of competing risks of death amongst patients with untreated UTUC is poised to aid in counselling and decision making for those at high perioperative risk and potentially considering a watchful waiting programme. As there is currently limited data on the outcome associated with non-definitive treatment, we used a large national cancer registry to evaluate the survival outcomes in this population.
Patients and Methods
Patient information was obtained from a case listing session using the Surveillance, Epidemiology, and End Results (SEER) 18 database of the USA National Cancer Institute. The SEER system records patient demographics, tumour extent, treatment, and resultant cancer outcomes from 18 registries from around the USA, representing 28% of the USA population [11] . Only patients with localised, histologically confirmed ureteric and kidney and renal pelvis cancers (International Classification of Diseases for Oncology [ICD-O] site codes C65.9 and C66.9) between the years of 1993 and 2013 were eligible for inclusion in our non-definitive cohort. Additionally, cases were selected for by using specific ICD-O third edition histological codes (Table S1 ). Cases were excluded if surgical status or survival were unknown. Furthermore, patients who underwent endoscopic procedures for tumour eradication including ablation/resection were excluded, and any form of intervention including endoscopic treatment was considered surgical management. For patients in the non-definitive cohort, patients who were aged <60 years were excluded to limit coding errors in the SEER database who may have instead received aggressive therapy. A flowchart of the SEER query and exclusions can be seen in Figure S1 . For statistical analysis, the chi-squared test and independent t-test were used to compare categorical and continuous variables between groups, respectively. The Mann-Whitney test was used for comparisons of continuous data without a normal distribution. Demographic and tumour characteristics were compared between groups based on surgical status (surgery vs no surgery). Survival analysis was performed overall, by surgical status, and tumour characteristics. Tumours were considered low grade if classified as grade 1/2 and high grade if 3/4. Overall survival (OS) was defined as time from cancer diagnosis to death from any cause and disease-specific survival (DSS) was defined as time from diagnosis to death from disease. Survival analyses were performed using the Kaplan-Meier method, and differences between patient subgroups were compared with the log-rank test. Patients were censored if alive at the date of last contact or for DSS, if death occurred from another cause. For those who did not receive surgical intervention, the Nelson-Aalen estimate was used to assess the cumulative incidence of cancer-specific mortality (CSM) due to UTUC. This method was used for estimating CSM as Kaplan-Meier survival analysis can overestimate risk by failing to account for the competing risk of death from other causes [12] . A Fine and Gray competing risks regression model was used to examine factors that predicted worse DSS. An a ≤ 0.05 was used for statistical significance. All statistical analyses were performed using JMP version 11.2, IBM SPSS Statistics version 22, and R version 3.3.0 along with the 'rms', and 'cmprsk' packages.
Results
We identified 8 304 patients with localised UTUC, of whom 633 (7.6%) did not receive any form of definitive therapy. Demographic data and tumour characteristics grouped by treatment status are listed in Table 1 . Of note, patients managed non-definitively were older at diagnosis (median age 81 vs 71 years, P < 0.001) and had smaller tumours (median size 2.4 vs 3.0 cm, P < 0.001). The non-definitive cohort was more commonly White (89.3%). The primary site of the UTUC was the renal pelvis in 270 (42.7%) and the ureter in 363 (57.3%). Tumour grade was reported in 69.5%, and of those 193 (43.5%) and 251 (56.5%) were low-and high-grade, respectively. ICD-O-3 tumour histology was reported as 8120.3/TCC, not otherwise specified in 355 (56.1%), whilst 276 (43.6%) were classified as 8130.3/papillary TCC.
The median follow-up for the non-definitive and surgical cohorts was 3.5 and 6.3 years, respectively. The median OS for those managed non-definitively was significantly shorter compared to those in the surgical cohort (1.9 vs 7.8 years, respectively, P < 0.001, Fig. 1a) . The 3-year DSS for the nondefinitive cohort was 73.7%, which was significantly lower than the surgical cohort (92.4%, P < 0.001, Fig. 1b) . The 3-year cumulative incidence of CSM when accounting for competing risk of death was 26.3% (Fig. 2) .
The median OS for the non-definitive cohort with high-grade disease was significantly shorter compared to those with lowgrade disease (1.5 vs 3.4 years, P < 0.001; Fig. 3a) . The 3-year DSS for patients with high-grade disease was 65.1%. For the cohort with low-grade disease, the 3-year DSS was significantly better at 82.9% (P < 0.001; Fig. 3b) . Patients with the designation of papillary histology had significantly better DSS when compared to those without (3-year DSS was 80.1% vs 68.3%, P < 0.001; Fig. 3c ). Significant predictors of CSM in our competing risk model included older age (hazard ratio [HR] 1.05, P < 0.001), male sex (HR 0.716, P = 0.045), and high tumour grade (HR 1.88, P < 0.001). Histology was not found to be a significant predictor on multivariable analysis ( Table 2 ). As SEER histology is not centrally reviewed, we performed a separate model without histological information and found that age and grade retained an impact on survival trends with nearly identical HRs (Table S2 ). 
Discussion
Upper tract urothelial carcinoma is a relatively uncommon malignancy that is diagnosed in~2/100 000 individuals at risk per year [13] . About 55% of patients will present with in situ or localised disease, and another 8-9% will have distant metastasis at time of diagnosis [3] . UTUC can be a highly morbid disease that may cause haematuria, flank pain, and in some rare instances, the development of an abdominal mass. With a peak age of incidence ranging between 70 and 90 years, many cases can be complicated by age-related comorbidities, such as diabetes and chronic kidney disease [14] . For these patients, the 'gold standard' treatment of radical nephroureterectomy can pose significant postoperative risks, such as progression to ESRD or perioperative morbidity and prolonged hospital admission.
Nephron-sparing procedures with segmental ureterectomy or endoscopic ablation have been used in patients with UTUC with a need for renal preservation; however, these procedures still pose risks of significant perioperative complications [15, 16] . It should also be noted that a nephron-sparing approach for UTUC is limited to select cases based on tumour location, grade, and stage. In addition, there is a measurable risk of oncological failure. One large series found that after 5 years, 50% of patients who underwent endoscopic ablation for non-invasive UTUC had a local recurrence [16, 17] . Given the risks of various surgical options and the likelihood of failure of endoscopic ablation when inappropriately used, patients who have a short lifeexpectancy may opt to forego curative therapy and choose a more conservative approach.
To our knowledge, the present study represents the first report of survival outcomes in patients with localised UTUC managed non-definitively, something akin to a watchfulwaiting approach classically described in other urological malignancies. We found that the non-definitive cohort had modest survival outcomes, with a median OS of 1.9 years and a cumulative CSM of 26.3% at 3 years. Not surprisingly, patients in the non-definitive cohort were older with smaller tumours when compared with patients who underwent surgical management. On multivariable analysis, older age at diagnosis and high tumour grade were independent predictors of poorer CSM (HR 1.05 and 1.88, respectively), whilst male sex was associated with more favourable CSM (HR 0.716). Our present findings are corroborated by a recent systematic review by Petrelli et al. [18] , which assessed factors associated with an increased risk of death in patients with UTUC. Their meta-analysis of 20 articles revealed that age (HR 1.04; 95% CI 1.02-1.06; P < 0.001) and high tumour grade (HR 1.7; 95% CI 1.38-2.09; P < 0.001) were both independent predictors of mortality. Although our present analysis is limited in the clinicopathological factors associated with non-operative management, the findings may be useful for selection and counselling in patients whom are borderline surgical candidates and are considering a watchful-waiting approach.
Watchful waiting is an expectant management strategy that has been adopted in prostate cancer to limit overtreatment. Watchful waiting is offered to patients who are unfit for definitive therapy or have a very short life-expectancy attributable to competing causes of mortality. This approach involves disease monitoring with the expectation of delivering palliative treatment upon symptomatic progression [19] . This is in stark contrast to active surveillance programmes wherein curative therapy is offered only after a period of monitoring and subsequent concerns for risk of oncological progression to a different disease stage. However, we acknowledge that the paradigm of surveillance or observation is somewhat different compared to these other malignancies given the biology of UTUC.
The watchful-waiting approach in patients with UTUC has had little mention as a treatment option in the literature, perhaps due to the relatively aggressive biology of the disease and over uncertainty regarding both triggers for intervention and the appropriate palliative therapies to be considered. For patients with development of symptoms, e.g. haematuria, local treatment may be feasible with radiation or embolisation [20, 21] . For patients who are placed on watchful waiting and develop systemic progression, metastatic UC is uniformly fatal. Upon symptomatic distant progression, it is reasonable to consider palliative options in this population, as long as the toxicity profile is acceptable and quality of life can be maintained as long as feasible. Traditional systemic therapies for UC with platinum-based agents carry significant toxicity, especially in older frail patients. Similarly, as these agents are cleared by the kidneys; which in this case, may be obstructed from a urothelial mass; inadequate filtration can limit dosing of effective therapy. Perhaps potentially less toxic agents now approved for UC could increase utilisation of a watchfulwaiting approach. Immunotherapy with checkpoint inhibitors, including both programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies, represent a novel strategy to treat advanced UTUC [22] . Several checkpoint inhibitors are now approved as second-line therapy for metastatic UC and could play a role in palliative UTUC treatment, potentially expanding the future role of watchful waiting in this disease [10, 23, 24] .
Whilst we review the outcome of patients with localised UTUC managed non-operatively, further study of this treatment option should be pursued as we must recognise several limitations of our study. Due to the nature of this retrospective population-based cohort, we did not have access to detailed clinical information such as comorbidities and clinical tumour stage based on clinical interpretation of imaging modalities. These are characteristics that have been previously documented to affect survival in patients with UTUC. Furthermore, tumour histology was not assessed under central pathology review and is liable to inter-observer disagreement, especially for the designation of SEER papillary histology. In addition, our query was limited to only histologically confirmed UTUC and would not include those patients with only radiographic evidence of disease that could have been too frail to make a pathological diagnosis. We also acknowledge that for non-operative candidates, tumour size measurements were determined by radiographic imaging, which may have been less accurate in earlier years of diagnosis. Moreover, patients may have received supportive therapy for their disease which, due to coding limitations, we would not have access to. Despite these limitations, the large sample size and detailed clinical follow-up along with relevant demographic and tumour information has allowed us to describe relevant survival outcomes in the UTUC population managed non-definitively and may be useful for counselling patients who are not surgical candidates.
Conclusions
Patients with localised UTUC who are managed nonoperatively may exhibit extended survival in select cases. The median OS for this approach is~2 years. The 3-year cumulative incidence of CSM in this cohort was 26.3%. In addition, factors such as age at diagnosis and tumour grade may impact CSM. The 3-year DSS for patients with high- 
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